New Market Research Report: Greece Pharmaceuticals & Healthcare Report Q3 2013
The Greek pharmaceutical market will continue to be characterised by mandated price reductions, state intervention in pharmaceutical trade and regressive revenue taxes. Although there have been positive developments towards the payment of hospital debts, the Greek state will need to cut healthcare costs and drive efficiency to prevent debt from building up again. Moreover, the Greek government will continue to shift the burden of healthcare spending onto its citizens, requiring co-payments for expensive drugs and payments for outpatient visits.
View full press release